Minireview
Copyright ©2013 Baishideng. All rights reserved.
World J Meta-Anal. May 26, 2013; 1(1): 8-9
Published online May 26, 2013. doi: 10.13105/wjma.v1.i1.8
Sirturo (Bedaquiline): The first new anti tubercular drug in decades
Krishna Undela
Krishna Undela, Department of Pharmacy Practice, JSS College of Pharmacy, JSS University, Sri Shivarathreeshwara Nagar, Mysore 570015, Karnataka, India
Author contributions: Undela K drafted the protocol, did the literature search and wrote the manuscript.
Correspondence to: Mr. Krishna Undela, Department of Pharmacy Practice, JSS College of Pharmacy, JSS University, Sri Shivarathreeshwara Nagar, Mysore 570015, Karnataka, India. krishnaundela@gmail.com
Telephone: +91-998-6779870 Fax: +91-821-2548359
Received: January 30, 2013
Revised: February 22, 2013
Accepted: March 6, 2013
Published online: May 26, 2013
Core Tip

Core tip: The US Food and Drug Administration granted accelerated approval to Janseen Therapeutics “Sirturo (Bedaquiline)”, a diarylquinoline anti mycobacterial drug on December 28, 2012 as part of combination therapy in adults (≥ 18 years) to treat multidrug resistant tuberculosis when other alternatives are not available.